Anavex Life Sciences Corp (AVXL)

[TempePhil]

Investor, fair enough. It is certainly indicative, as Anavex was comfortable enough with the data (small sample size, no placebo) etc, to plot their data. I mapped Lilly's data to it. It was intended to be a back of the napkin, visual view of where Lilly stood with respect to A273, and I think it serves that purpose well. We rarely get perfect/easy data, and I maintain, Lilly's trial and Anavex's trial were very similar trials (patient ages, inclusion parameters..) and this close of an apples to apples comparison, is actually rare to find.

Agreed, when we see full data from Anavex's current trial, and full data from the Lilly trial we will MAY have a very accurate comparison. I feel it will still look similar to what I presented.

If it is not useful to some, then that is certainly fine, and understandable.